Evotec and Apeiron Biologics entered into a research collaboration to develop immunomodulatory lead compounds for the treatment of cancer. Apeiron Biologics will contribute in vitro and in vivo pharmacology expertise to this collaboration while Evotec will be responsible for medicinal chemistry as well as chemical proteomics. The collaboration is based on the successful outcome of a phenotypic high throughput screen previously commissioned by Apeiron Biologics to Evotec.
Last year, Evotec entered several collaborations. Most recently, the company signed a license agreement with Janssen regarding Evotec's NR2B subtype-selective NMDA-antagonist portfolio for development against diseases in the field of depression. Evotec also teamed up with Probiodrug on the development of drugs for the treatment of Alzheimer's disease.
In 2010, Apeiron Biologics worked with Evotec to identify small molecule modulators of DREAM (downstream regulatory element antagonistic modulator), a target involved in perception of pain.